BLINATUMOMAB

BLINATUMOMAB was reported 10722 times

BLINATUMOMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 LEUKAEMIC INFILTRATION EXTRAMEDULLARY 193 0.7569
1 LINEAGE SWITCH LEUKAEMIA 35 0.6604
2 ACUTE LYMPHOCYTIC LEUKAEMIA REFRACTORY 84 0.6222
3 PRECURSOR B-LYMPHOBLASTIC LYMPHOMA RECURRENT 15 0.5357
4 CENTRAL NERVOUS SYSTEM LEUKAEMIA 204 0.5191
5 LEUKAEMIC INFILTRATION RENAL 11 0.4583
6 B PRECURSOR TYPE ACUTE LEUKAEMIA 172 0.4433
7 ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT 1121 0.4340
8 BONE MARROW LEUKAEMIC CELL INFILTRATION 31 0.3780
9 CD19 ANTIGEN LOSS 5 0.3125
10 MINIMAL RESIDUAL DISEASE 102 0.2112
11 B-CELL TYPE ACUTE LEUKAEMIA 139 0.1894
12 GERM CELL NEOPLASM 4 0.1818
13 CSF LYMPHOCYTE COUNT INCREASED 11 0.1774
14 COSTAL CARTILAGE FRACTURE 6 0.1765
15 ACUTE BIPHENOTYPIC LEUKAEMIA 16 0.1720
16 B-CELL APLASIA 32 0.1240
17 ASPIRATION BONE MARROW ABNORMAL 16 0.1185
18 BLAST CELL COUNT INCREASED 122 0.1164
19 CSF CELL COUNT INCREASED 17 0.1149
20 LEUKAEMIA CUTIS 15 0.0974
21 TRANSPLANTATION COMPLICATION 39 0.0929
22 ACUTE LYMPHOCYTIC LEUKAEMIA 251 0.0886
23 TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA 55 0.0838
24 METASTASES TO RETROPERITONEUM 12 0.0706
25 BLAST CELL COUNT DECREASED 5 0.0685
26 METASTASES TO MUSCLE 12 0.0663
27 VASCULAR ACCESS SITE OCCLUSION 5 0.0633
28 HAEMATOPOIETIC STEM CELL MOBILISATION 4 0.0625
29 HAEMOLYTIC TRANSFUSION REACTION 4 0.0615
30 BLAST CELLS PRESENT 28 0.0582
31 CYTOKINE RELEASE SYNDROME 1150 0.0573
32 PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION 7 0.0560
33 ACHROMOBACTER INFECTION 6 0.0500
34 PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA 8 0.0491
35 METAMYELOCYTE COUNT INCREASED 7 0.0470
36 SPONTANEOUS BACTERIAL PERITONITIS 11 0.0451
37 CHRONIC GRAFT VERSUS HOST DISEASE IN EYE 9 0.0443
38 POST-DEPLETION B-CELL RECOVERY 5 0.0439
39 LEUKAEMIC INFILTRATION 6 0.0429
40 HEPATIC CALCIFICATION 7 0.0424
41 VASCULAR DEVICE OCCLUSION 14 0.0413
42 SECONDARY HYPERTHYROIDISM 4 0.0412
43 PHILADELPHIA CHROMOSOME POSITIVE 30 0.0410
44 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 242 0.0408
45 ACUTE MOTOR-SENSORY AXONAL NEUROPATHY 9 0.0391
46 GRAFT VERSUS HOST DISEASE IN EYE 9 0.0390
47 HUMAN HERPESVIRUS 6 ENCEPHALITIS 11 0.0387
48 CD19 LYMPHOCYTES DECREASED 5 0.0385
49 MYELOCYTE COUNT INCREASED 7 0.0372
50 CRYPTOCOCCAL FUNGAEMIA 5 0.0350
51 GRAFT VERSUS HOST DISEASE IN SKIN 76 0.0345
52 BONE MARROW NECROSIS 8 0.0342
53 ADRENOMEGALY 7 0.0337
54 ADENOVIRAL HAEMORRHAGIC CYSTITIS 7 0.0337
55 NEUROTOXICITY 584 0.0333
56 CHLOROMA 14 0.0332
57 CHRONIC GRAFT VERSUS HOST DISEASE ORAL 8 0.0327
58 GRAFT VERSUS HOST DISEASE IN LIVER 23 0.0321
59 FUSARIUM INFECTION 22 0.0314
60 TRICHOSPORON INFECTION 12 0.0296
61 GRAFT VERSUS HOST DISEASE IN GASTROINTESTINAL TRACT 62 0.0291
62 METASTASES TO SPLEEN 12 0.0291
63 DEVICE RELATED BACTERAEMIA 9 0.0290
64 RETROPERITONEAL MASS 4 0.0290
65 LEUKAEMIA RECURRENT 49 0.0290
66 VENOOCCLUSIVE DISEASE 71 0.0283
67 SUBDURAL HYGROMA 8 0.0263
68 METASTASES TO BONE MARROW 13 0.0260
69 ASPERGILLUS TEST POSITIVE 8 0.0260
70 ACUTE GRAFT VERSUS HOST DISEASE 119 0.0260
71 ALLOGENIC STEM CELL TRANSPLANTATION 4 0.0253
72 VENOOCCLUSIVE LIVER DISEASE 119 0.0241
73 ACUTE MYELOMONOCYTIC LEUKAEMIA 6 0.0238
74 FIBRIN DEGRADATION PRODUCTS INCREASED 7 0.0236
75 INTERLEUKIN LEVEL INCREASED 13 0.0236
76 ACUTE GRAFT VERSUS HOST DISEASE IN SKIN 64 0.0231
77 GRAFT VERSUS HOST DISEASE IN LUNG 11 0.0230
78 CHRONIC GRAFT VERSUS HOST DISEASE 81 0.0224
79 INFUSION SITE HAEMORRHAGE 73 0.0222
80 ACUTE MONOCYTIC LEUKAEMIA 4 0.0220
81 BLOOD LACTATE DEHYDROGENASE DECREASED 7 0.0210
82 CHRONIC GRAFT VERSUS HOST DISEASE IN SKIN 19 0.0205
83 MONOCYTOSIS 12 0.0193
84 CHRONIC GRAFT VERSUS HOST DISEASE IN LIVER 7 0.0192
85 REFRACTORY CANCER 4 0.0187
86 ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE 26 0.0184
87 TRACHEITIS 14 0.0184
88 DEVICE RELATED THROMBOSIS 18 0.0183
89 CATHETER SITE THROMBOSIS 5 0.0182
90 SYSTEMIC MYCOSIS 21 0.0180
91 DISSEMINATED MUCORMYCOSIS 7 0.0178
92 TRANSPLANT EVALUATION 9 0.0177
93 ENGRAFTMENT SYNDROME 10 0.0169
94 CHRONIC MYELOID LEUKAEMIA RECURRENT 9 0.0165
95 DEVICE PROGRAMMING ERROR 5 0.0158
96 LYMPHOCYTIC LEUKAEMIA 6 0.0147
97 KLEBSIELLA BACTERAEMIA 14 0.0147
98 GRAFT VERSUS HOST DISEASE 106 0.0147
99 INTENTION TREMOR 8 0.0141
100 MYELOID LEUKAEMIA 7 0.0140
101 ESCHERICHIA BACTERAEMIA 31 0.0132
102 DECREASED EYE CONTACT 4 0.0132
103 CYTOKINE STORM 9 0.0131
104 ERYTHROPOIESIS ABNORMAL 4 0.0131
105 LOWER RESPIRATORY TRACT INFECTION FUNGAL 5 0.0129
106 APRAXIA 19 0.0128
107 GENE MUTATION 25 0.0126
108 AGNOSIA 3 0.0126
109 PARAKERATOSIS 4 0.0123
110 TUMOUR ASSOCIATED FEVER 5 0.0122
111 FUNGAEMIA 19 0.0121
112 MUSCLE STRENGTH ABNORMAL 5 0.0119
113 DISSEMINATED CRYPTOCOCCOSIS 9 0.0119
114 COMPLICATIONS OF TRANSPLANT SURGERY 6 0.0119
115 HYPOGAMMAGLOBULINAEMIA 78 0.0119
116 CAPILLARY LEAK SYNDROME 24 0.0116
117 DYSMETRIA 7 0.0116
118 JAW OPERATION 10 0.0112
119 ACUTE GRAFT VERSUS HOST DISEASE IN LIVER 8 0.0111
120 COMPLICATIONS OF BONE MARROW TRANSPLANT 4 0.0111
121 CATHETER SITE RASH 5 0.0111
122 HYPERPHOSPHATAEMIA 23 0.0107
123 NEOPLASM RECURRENCE 36 0.0106
124 LEUKOENCEPHALOPATHY 39 0.0105
125 CYSTITIS VIRAL 4 0.0104
126 TUMOUR LYSIS SYNDROME 90 0.0102
127 BLOOD FIBRINOGEN INCREASED 8 0.0101
128 ARACHNOIDITIS 7 0.0101
129 OCCUPATIONAL EXPOSURE TO PRODUCT 65 0.0101
130 INCORRECT DRUG ADMINISTRATION RATE 43 0.0101
131 NEUROLOGICAL SYMPTOM 57 0.0100
132 CSF TEST ABNORMAL 5 0.0099
133 BLOOD FIBRINOGEN DECREASED 11 0.0096
134 POSTURING 5 0.0096
135 HEPATOBILIARY DISEASE 6 0.0096
136 B-LYMPHOCYTE COUNT DECREASED 13 0.0095
137 BLOOD PRODUCT TRANSFUSION DEPENDENT 4 0.0095
138 PROCALCITONIN INCREASED 11 0.0094
139 HYPERFERRITINAEMIA 4 0.0093
140 DIAPHRAGMATIC DISORDER 7 0.0092
141 EPSTEIN-BARR VIRUS INFECTION REACTIVATION 12 0.0091
142 INTERCEPTED PRODUCT PREPARATION ERROR 111 0.0090
143 METAPNEUMOVIRUS INFECTION 7 0.0089
144 CYTOPENIA 109 0.0089
145 IMMUNOGLOBULINS DECREASED 12 0.0087
146 IIIRD NERVE PARALYSIS 7 0.0087
147 TRANSPLANT FAILURE 21 0.0086
148 DEVICE INFUSION ISSUE 21 0.0085
149 MYOCARDIAL INJURY 9 0.0080
150 ADENOVIRUS INFECTION 23 0.0079
151 HYPERLEUKOCYTOSIS 7 0.0079
152 PNEUMONIA FUNGAL 31 0.0079
153 CYTOMEGALOVIRUS TEST POSITIVE 14 0.0078
154 PARVOVIRUS B19 INFECTION 7 0.0078
155 SLOW RESPONSE TO STIMULI 10 0.0077
156 BK VIRUS INFECTION 26 0.0077
157 FEBRILE INFECTION 9 0.0076
158 ENTEROCOLITIS INFECTIOUS 7 0.0076
159 ENTEROCOCCAL BACTERAEMIA 8 0.0075
160 SUPERIOR SAGITTAL SINUS THROMBOSIS 6 0.0075
161 HAPTOGLOBIN DECREASED 6 0.0074
162 ACUTE LEUKAEMIA 12 0.0074
163 HYPERTROPHY 4 0.0074
164 MUCORMYCOSIS 19 0.0073
165 INTERCEPTED PRODUCT ADMINISTRATION ERROR 56 0.0073
166 HYPOFIBRINOGENAEMIA 7 0.0071
167 VIRAL HAEMORRHAGIC CYSTITIS 5 0.0070
168 CYTOMEGALOVIRUS INFECTION REACTIVATION 31 0.0070
169 THROMBOSIS IN DEVICE 23 0.0070
170 MENINGITIS BACTERIAL 10 0.0070
171 LYMPHOCYTE MORPHOLOGY ABNORMAL 4 0.0069
172 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 52 0.0069
173 BLOOD IMMUNOGLOBULIN G DECREASED 17 0.0069
174 MONOCYTE COUNT DECREASED 8 0.0066
175 CEREBRAL ASPERGILLOSIS 4 0.0065
176 THERAPY NON-RESPONDER 291 0.0065
177 PERIPHERAL MOTOR NEUROPATHY 9 0.0064
178 INTENSIVE CARE 9 0.0063
179 HYPOPROTEINAEMIA 12 0.0063
180 NEUTROPENIC COLITIS 13 0.0063
181 ASPERGILLUS INFECTION 41 0.0062
182 DEVICE RELATED INFECTION 96 0.0062
183 CARDIAC VENTRICULAR THROMBOSIS 8 0.0062
184 VASCULAR ACCESS COMPLICATION 5 0.0062
185 RHINOVIRUS INFECTION 24 0.0062
186 ANGIOCENTRIC LYMPHOMA 3 0.0061
187 SYSTEMIC CANDIDA 15 0.0060
188 MARROW HYPERPLASIA 4 0.0059
189 T-LYMPHOCYTE COUNT DECREASED 4 0.0059
190 PSEUDOMONAL BACTERAEMIA 5 0.0059
191 HEPATOTOXICITY 130 0.0058
192 ENCEPHALOPATHY 142 0.0058
193 JUGULAR VEIN THROMBOSIS 10 0.0056
194 INFECTION IN AN IMMUNOCOMPROMISED HOST 4 0.0056
195 STAPHYLOCOCCAL BACTERAEMIA 24 0.0055
196 MUTISM 8 0.0055
197 SYSTEMIC SCLERODERMA 4 0.0055
198 CYTOMEGALOVIRUS INFECTION 91 0.0055
199 TRANSPLANT 13 0.0055
200 SPINAL CORD DISORDER 9 0.0055
201 NERVOUS SYSTEM DISORDER 167 0.0053
202 ACQUIRED GENE MUTATION 7 0.0053
203 KLEBSIELLA SEPSIS 6 0.0053
204 HUMAN HERPESVIRUS 6 INFECTION 10 0.0053
205 NEUTROPENIC INFECTION 5 0.0052
206 BLOOD CHLORIDE INCREASED 9 0.0052
207 CYSTITIS HAEMORRHAGIC 21 0.0052
208 PRODUCT PREPARATION ERROR 107 0.0052
209 CYTOMEGALOVIRUS ENTEROCOLITIS 4 0.0052
210 SUPERINFECTION BACTERIAL 4 0.0050
211 DYSGRAPHIA 33 0.0050
212 THERAPEUTIC RESPONSE DELAYED 14 0.0050
213 SINUSITIS FUNGAL 4 0.0050
214 DEVICE RELATED SEPSIS 10 0.0050
215 CLOSTRIDIUM COLITIS 6 0.0049
216 BLAST CRISIS IN MYELOGENOUS LEUKAEMIA 6 0.0049
217 QUADRIPLEGIA 10 0.0049
218 CSF PROTEIN INCREASED 4 0.0048
219 FUNGAL SEPSIS 4 0.0048
220 STEM CELL TRANSPLANT 12 0.0048
221 ARTERITIS 3 0.0047
222 CEREBRAL VENOUS SINUS THROMBOSIS 4 0.0047
223 FEBRILE NEUTROPENIA 313 0.0047
224 POLYOMAVIRUS VIRAEMIA 5 0.0047
225 DISSEMINATED INTRAVASCULAR COAGULATION 66 0.0047
226 BACTERIAL SEPSIS 15 0.0046
227 APHASIA 139 0.0046
228 PARAINFLUENZAE VIRUS INFECTION 7 0.0046
229 HAEMORRHAGIC DISORDER 5 0.0046
230 STREPTOCOCCAL BACTERAEMIA 5 0.0046
231 PSEUDOMONAL SEPSIS 8 0.0046
232 ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED 23 0.0045
233 INTERCEPTED MEDICATION ERROR 21 0.0045
234 ESCHERICHIA SEPSIS 13 0.0045
235 CANDIDA SEPSIS 4 0.0045
236 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 149 0.0044
237 CATHETER SITE HAEMORRHAGE 11 0.0044
238 CENTRAL NERVOUS SYSTEM INFECTION 5 0.0044
239 SERUM FERRITIN INCREASED 23 0.0044
240 BODY TEMPERATURE ABNORMAL 8 0.0043
241 BLOOD CULTURE POSITIVE 13 0.0043
242 ALPHA HAEMOLYTIC STREPTOCOCCAL INFECTION 4 0.0043
243 C-REACTIVE PROTEIN 4 0.0043
244 PRURITUS ALLERGIC 5 0.0043
245 HYPORESPONSIVE TO STIMULI 5 0.0043
246 ESCHERICHIA URINARY TRACT INFECTION 18 0.0042
247 MYELOPATHY 8 0.0042
248 NEUTROPENIC SEPSIS 30 0.0042
249 ESCHERICHIA TEST POSITIVE 5 0.0042
250 ENTEROBACTER INFECTION 7 0.0042
251 SECONDARY IMMUNODEFICIENCY 5 0.0041
252 PERIPHERAL SENSORY NEUROPATHY 24 0.0041
253 MYELOSUPPRESSION 143 0.0040
254 DILATED CARDIOMYOPATHY 4 0.0040
255 ENTEROCOCCAL INFECTION 19 0.0039
256 HAEMANGIOMA 9 0.0039
257 HAEMATOTOXICITY 37 0.0039
258 BACTERAEMIA 46 0.0039
259 POSTICTAL STATE 4 0.0038
260 SOFT TISSUE INFECTION 7 0.0038
261 OBLITERATIVE BRONCHIOLITIS 5 0.0038
262 HYPERAMMONAEMIA 19 0.0038
263 THROMBOTIC MICROANGIOPATHY 37 0.0038
264 EXTRADURAL HAEMATOMA 5 0.0038
265 ACUTE MYELOID LEUKAEMIA RECURRENT 8 0.0037
266 PERIODONTITIS 8 0.0037
267 STENOTROPHOMONAS INFECTION 5 0.0037
268 KIDNEY ENLARGEMENT 4 0.0037
269 METABOLIC ENCEPHALOPATHY 11 0.0037
270 THERAPY PARTIAL RESPONDER 57 0.0037
271 MULTIPLE ORGAN DYSFUNCTION SYNDROME 103 0.0036
272 EPSTEIN-BARR VIRAEMIA 4 0.0036
273 HYPERTRIGLYCERIDAEMIA 21 0.0036
274 TONIC CONVULSION 5 0.0035
275 PNEUMATOSIS INTESTINALIS 10 0.0035
276 CARDIOTOXICITY 31 0.0035
277 NEUROLOGICAL DECOMPENSATION 8 0.0035
278 PYREXIA 1187 0.0034
279 RADICULOPATHY 9 0.0034
280 BONE MARROW FAILURE 69 0.0034
281 BRAIN HERNIATION 10 0.0033
282 BLOOD LACTATE DEHYDROGENASE INCREASED 53 0.0033
283 ASPARTATE AMINOTRANSFERASE ABNORMAL 5 0.0033
284 FEBRILE CONVULSION 4 0.0033
285 PNEUMONIA KLEBSIELLA 6 0.0033
286 LANGUAGE DISORDER 7 0.0032
287 NEUTROPHIL COUNT ABNORMAL 9 0.0032
288 PSEUDOMONAS INFECTION 27 0.0031
289 TRANSAMINASES INCREASED 70 0.0031
290 PNEUMONIA VIRAL 10 0.0031
291 HEPATOSPLENOMEGALY 8 0.0031
292 BRONCHOPULMONARY ASPERGILLOSIS 24 0.0031
293 VASCULAR DEVICE INFECTION 14 0.0031
294 HERPES SIMPLEX 20 0.0031
295 NEUTROPHIL COUNT DECREASED 125 0.0031
296 APLASIA 6 0.0031
297 BONE LESION 11 0.0030
298 CYTOMEGALOVIRUS COLITIS 7 0.0030
299 GENERALISED TONIC-CLONIC SEIZURE 50 0.0030
300 HYPERTRANSAMINASAEMIA 21 0.0030
301 PANCREATITIS CHRONIC 7 0.0030
302 BRAIN NATRIURETIC PEPTIDE INCREASED 9 0.0029
303 VIRAEMIA 4 0.0029
304 LUNG CONSOLIDATION 8 0.0029
305 PRODUCT LEAKAGE 16 0.0028
306 ALANINE AMINOTRANSFERASE ABNORMAL 6 0.0028
307 DEVICE CONNECTION ISSUE 6 0.0028
308 WHITE BLOOD CELL COUNT ABNORMAL 18 0.0028
309 PANCYTOPENIA 157 0.0028
310 TRANSPLANT DYSFUNCTION 5 0.0028
311 ATAXIA 33 0.0028
312 OLIGURIA 17 0.0027
313 AMYLASE INCREASED 10 0.0027
314 BLOOD BILIRUBIN INCREASED 73 0.0027
315 FACIAL PARALYSIS 23 0.0027
316 INTRACRANIAL PRESSURE INCREASED 15 0.0027
317 MENINGITIS ASEPTIC 12 0.0027
318 CATHETER SITE INFECTION 10 0.0026
319 BONE MARROW TRANSPLANT 5 0.0026
320 ARTERIAL HAEMORRHAGE 3 0.0026
321 LIVER FUNCTION TEST INCREASED 56 0.0026
322 GASTROINTESTINAL INJURY 7 0.0026
323 LYMPHOCYTE COUNT DECREASED 46 0.0026
324 HYPERPYREXIA 11 0.0026
325 INFERTILITY FEMALE 4 0.0026
326 CORONAVIRUS INFECTION 17 0.0026
327 BILIRUBIN CONJUGATED INCREASED 6 0.0026
328 SUBDURAL HAEMORRHAGE 7 0.0026
329 FIBRIN D DIMER INCREASED 9 0.0025
330 CELL DEATH 5 0.0025
331 PNEUMOCYSTIS JIROVECII PNEUMONIA 25 0.0025
332 PLATELET COUNT ABNORMAL 15 0.0025
333 STATUS EPILEPTICUS 28 0.0025
334 SCLERODERMA 9 0.0025
335 CYTOMEGALOVIRUS VIRAEMIA 11 0.0025
336 VENTRICULAR ARRHYTHMIA 9 0.0025
337 CLOSTRIDIUM DIFFICILE COLITIS 26 0.0024
338 LYMPHOCYTE COUNT INCREASED 8 0.0024
339 NEUTROPENIA 333 0.0024
340 ATRIAL THROMBOSIS 5 0.0024
341 DEVICE OCCLUSION 34 0.0024
342 SEIZURE 279 0.0024
343 RED CELL DISTRIBUTION WIDTH INCREASED 10 0.0024
344 DISEASE COMPLICATION 11 0.0024
345 PULSELESS ELECTRICAL ACTIVITY 10 0.0024
346 KLEBSIELLA INFECTION 12 0.0024
347 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 9 0.0024
348 GAZE PALSY 4 0.0023
349 LACTOSE INTOLERANCE 6 0.0023
350 ADVERSE REACTION 31 0.0023
351 MUCOSAL INFLAMMATION 61 0.0023
352 CEREBROVASCULAR DISORDER 7 0.0023
353 BONE MARROW DISORDER 7 0.0023
354 ENCEPHALITIS 16 0.0023
355 GASTROINTESTINAL TOXICITY 11 0.0023
356 EMBOLISM 19 0.0023
357 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 5 0.0023
358 ANION GAP INCREASED 3 0.0022
359 PRODUCT STORAGE ERROR 196 0.0022
360 ORGANISING PNEUMONIA 11 0.0022
361 PAPILLOEDEMA 10 0.0022
362 MONOPARESIS 4 0.0022
363 HEPATITIS B REACTIVATION 7 0.0022
364 METASTASES TO MENINGES 5 0.0022
365 MENTAL STATUS CHANGES 61 0.0022
366 APNOEA 17 0.0022
367 THROMBOCYTOPENIA 234 0.0021
368 SLOW SPEECH 5 0.0021
369 PNEUMONIA CYTOMEGALOVIRAL 4 0.0021
370 PULMONARY HAEMORRHAGE 16 0.0020
371 COVID-19 PNEUMONIA 24 0.0020
372 DRUG RESISTANCE 52 0.0020
373 ACUTE PSYCHOSIS 5 0.0020
374 ALANINE AMINOTRANSFERASE INCREASED 124 0.0020
375 HEPATIC FUNCTION ABNORMAL 75 0.0020
376 PROTHROMBIN TIME PROLONGED 12 0.0020
377 FACIAL PARESIS 7 0.0020
378 SHOCK HAEMORRHAGIC 16 0.0020
379 ENDOCARDITIS 10 0.0019
380 DIFFUSE LARGE B-CELL LYMPHOMA 15 0.0019
381 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 57 0.0019
382 ALTERED STATE OF CONSCIOUSNESS 42 0.0019
383 HYPERBILIRUBINAEMIA 20 0.0019
384 VARICELLA ZOSTER VIRUS INFECTION 4 0.0019
385 ACCIDENTAL EXPOSURE TO PRODUCT 198 0.0019
386 LYMPHOPENIA 27 0.0019
387 STAPHYLOCOCCUS TEST POSITIVE 4 0.0019
388 LUNG OPACITY 5 0.0019
389 NON-CARDIAC CHEST PAIN 6 0.0019
390 CARDIAC DYSFUNCTION 7 0.0019
391 PROTEIN TOTAL DECREASED 7 0.0019
392 INFECTION 268 0.0018
393 HYPOXIA 65 0.0018
394 FULL BLOOD COUNT DECREASED 37 0.0018
395 CEREBELLAR SYNDROME 4 0.0018
396 STAPHYLOCOCCAL SEPSIS 9 0.0018
397 HEPATIC ENCEPHALOPATHY 17 0.0018
398 HAEMOLYSIS 14 0.0018
399 PLEURITIC PAIN 5 0.0018
400 HYPOALBUMINAEMIA 14 0.0018
401 ACUTE MYELOID LEUKAEMIA 28 0.0018
402 ILEUS PARALYTIC 8 0.0018
403 DISORIENTATION 71 0.0018
404 HYPERGLYCAEMIA 65 0.0018
405 ENDOTRACHEAL INTUBATION 5 0.0018
406 EPSTEIN-BARR VIRUS INFECTION 11 0.0018
407 DELIRIUM 61 0.0018
408 BRAIN OEDEMA 22 0.0017
409 ENTEROCOLITIS 10 0.0017
410 TREMOR 287 0.0017
411 SEPSIS 192 0.0017
412 WHITE BLOOD CELL COUNT INCREASED 66 0.0017
413 PARTIAL SEIZURES 9 0.0017
414 RESPIRATORY TRACT INFECTION VIRAL 4 0.0017
415 BLOOD LACTIC ACID INCREASED 9 0.0017
416 HYPERURICAEMIA 7 0.0017
417 LUNG INFILTRATION 15 0.0017
418 LEUKAEMIA 16 0.0017
419 DISEASE RECURRENCE 80 0.0017
420 INTRA-ABDOMINAL HAEMORRHAGE 4 0.0017
421 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 16 0.0017
422 DYSARTHRIA 63 0.0017
423 GAMMA-GLUTAMYLTRANSFERASE INCREASED 37 0.0017
424 SEPTIC SHOCK 72 0.0017
425 CUTANEOUS VASCULITIS 6 0.0016
426 PRODUCT CONTAINER ISSUE 14 0.0016
427 HYPOPHOSPHATAEMIA 12 0.0016
428 DISEASE PROGRESSION 192 0.0016
429 ASPARTATE AMINOTRANSFERASE INCREASED 86 0.0016
430 NEOPLASM PROGRESSION 56 0.0016
431 HEMIPARESIS 27 0.0016
432 ELECTROENCEPHALOGRAM ABNORMAL 5 0.0016
433 COMMUNICATION DISORDER 6 0.0016
434 BODY TEMPERATURE INCREASED 32 0.0016
435 LIPASE INCREASED 12 0.0016
436 ABDOMINAL INFECTION 4 0.0016
437 SECOND PRIMARY MALIGNANCY 13 0.0016
438 PRODUCT TEMPERATURE EXCURSION ISSUE 8 0.0016
439 PULMONARY TOXICITY 11 0.0016
440 PORTAL VEIN THROMBOSIS 5 0.0015
441 HAEMORRHAGE INTRACRANIAL 23 0.0015
442 EPILEPSY 47 0.0015
443 HEPATITIS TOXIC 4 0.0015
444 PRODUCT ADMINISTRATION INTERRUPTED 12 0.0015
445 MYELODYSPLASTIC SYNDROME 22 0.0015
446 PLEURAL EFFUSION 92 0.0015
447 CEREBRAL ATROPHY 6 0.0015
448 PROTEIN TOTAL INCREASED 4 0.0015
449 PLATELET COUNT DECREASED 160 0.0015
450 COAGULOPATHY 25 0.0015
451 WHITE BLOOD CELL DISORDER 4 0.0015
452 ORGAN FAILURE 6 0.0015
453 SUBARACHNOID HAEMORRHAGE 15 0.0015
454 RECURRENT CANCER 6 0.0015
455 INFUSION SITE EXTRAVASATION 9 0.0014
456 CONFUSIONAL STATE 232 0.0014
457 HEPATIC FAILURE 43 0.0014
458 PULMONARY ALVEOLAR HAEMORRHAGE 8 0.0014
459 ACUTE RESPIRATORY DISTRESS SYNDROME 25 0.0014
460 HEPATIC CYTOLYSIS 18 0.0014
461 ACUTE RESPIRATORY FAILURE 27 0.0014
462 TREATMENT FAILURE 116 0.0014
463 SUBDURAL HAEMATOMA 20 0.0014
464 BLOOD ALBUMIN DECREASED 11 0.0014
465 BLOOD URIC ACID INCREASED 8 0.0014
466 TOXIC ENCEPHALOPATHY 7 0.0014
467 POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER 7 0.0014
468 C-REACTIVE PROTEIN INCREASED 50 0.0014
469 SPLENOMEGALY 16 0.0014
470 CANDIDA INFECTION 23 0.0014
471 IMMUNOSUPPRESSION 12 0.0014
472 CEREBRAL ISCHAEMIA 7 0.0014
473 NEURODERMATITIS 5 0.0013
474 PERICARDIAL EFFUSION 31 0.0013
475 HEPATIC NECROSIS 5 0.0013
476 HEPATOMEGALY 13 0.0013
477 CHEMOTHERAPY 5 0.0013
478 HYPOKALAEMIA 61 0.0013
479 FUNGAL INFECTION 44 0.0013
480 NEUROPATHY PERIPHERAL 125 0.0013
481 IMMUNE THROMBOCYTOPENIA 6 0.0013
482 CHRONIC MYELOID LEUKAEMIA 6 0.0013
483 BACTERIAL INFECTION 24 0.0013
484 CEREBRAL HAEMORRHAGE 46 0.0013
485 SPINAL CORD COMPRESSION 5 0.0013
486 TUBULOINTERSTITIAL NEPHRITIS 24 0.0013
487 LEUKOPENIA 64 0.0013
488 BLOOD CREATININE DECREASED 4 0.0013
489 HYPOCALCAEMIA 24 0.0013
490 LIVER INJURY 31 0.0013
491 VIRAL UPPER RESPIRATORY TRACT INFECTION 6 0.0013
492 CHOLESTASIS 24 0.0012
493 INCONTINENCE 13 0.0012
494 ARTERIOSCLEROSIS CORONARY ARTERY 8 0.0012
495 END STAGE RENAL DISEASE 22 0.0012
496 CLOSTRIDIUM DIFFICILE INFECTION 26 0.0012
497 BLOOD COUNT ABNORMAL 18 0.0012
498 DYSPHORIA 6 0.0012
499 STAPHYLOCOCCAL INFECTION 39 0.0012
500 PETIT MAL EPILEPSY 6 0.0012
501 TACHYCARDIA 104 0.0012
502 BLOOD CREATININE ABNORMAL 4 0.0012
503 LABORATORY TEST ABNORMAL 34 0.0012
504 UNEVALUABLE EVENT 87 0.0011
505 RESPIRATORY SYNCYTIAL VIRUS INFECTION 10 0.0011
506 HEPATIC ENZYME INCREASED 78 0.0011
507 EOSINOPHILIA 20 0.0011
508 BLOOD ALKALINE PHOSPHATASE INCREASED 28 0.0011
509 ASCITES 33 0.0011
510 DECREASED IMMUNE RESPONSIVENESS 11 0.0011
511 COMPRESSION FRACTURE 6 0.0011
512 RESPIRATORY FAILURE 81 0.0011
513 LIVER DISORDER 49 0.0011
514 COMPLICATION ASSOCIATED WITH DEVICE 16 0.0011
515 HICCUPS 9 0.0011
516 STOMATITIS 66 0.0011
517 HAEMOGLOBIN ABNORMAL 7 0.0011
518 IMMUNODEFICIENCY 16 0.0011
519 MALNUTRITION 12 0.0011
520 REFUSAL OF TREATMENT BY PATIENT 7 0.0011
521 PANCREATITIS 56 0.0011
522 GLOMERULAR FILTRATION RATE DECREASED 13 0.0011
523 PERONEAL NERVE PALSY 6 0.0011
524 GRANULOCYTOPENIA 6 0.0011
525 LEUKOCYTOSIS 19 0.0010
526 MENINGITIS 7 0.0010
527 WHITE BLOOD CELL COUNT DECREASED 113 0.0010
528 MYOPATHY 9 0.0010
529 PRODUCT ADMINISTRATION ERROR 21 0.0010
530 BLOOD CALCIUM INCREASED 9 0.0010
531 ADVERSE EVENT 94 0.0010
532 GASTROINTESTINAL INFECTION 9 0.0010
533 HEPATIC ENZYME ABNORMAL 5 0.0010
534 CORONARY ARTERY STENOSIS 5 0.0010
535 OPTIC NEURITIS 9 0.0010
536 AMMONIA INCREASED 5 0.0010
537 ARTHRITIS BACTERIAL 4 0.0010
538 SPEECH DISORDER 51 0.0010
539 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 8 0.0010
540 UNRESPONSIVE TO STIMULI 25 0.0010
541 CHOLANGITIS 6 0.0010
542 MUSCLE TWITCHING 22 0.0010
543 METASTASES TO LUNG 11 0.0010
544 COLITIS 36 0.0009
545 OSTEONECROSIS OF JAW 23 0.0009
546 HYDROCEPHALUS 5 0.0009
547 SHOCK 21 0.0009
548 CARDIOGENIC SHOCK 13 0.0009
549 OFF LABEL USE 793 0.0009
550 NO THERAPEUTIC RESPONSE 11 0.0009
551 CARDIAC FAILURE ACUTE 6 0.0009
552 LEFT VENTRICULAR DYSFUNCTION 6 0.0009
553 NEPHROPATHY TOXIC 10 0.0009
554 HYPERCALCAEMIA 11 0.0009
555 ANAL INCONTINENCE 8 0.0009
556 HYPOTHERMIA 9 0.0009
557 CHILLS 104 0.0009
558 DEPRESSED LEVEL OF CONSCIOUSNESS 35 0.0009
559 ACUTE HEPATIC FAILURE 12 0.0009
560 DRUG EFFECT LESS THAN EXPECTED 13 0.0009
561 LARGE INTESTINE PERFORATION 6 0.0009
562 RALES 5 0.0009
563 ANAEMIA 164 0.0009
564 PRODUCT LABEL CONFUSION 5 0.0009
565 RASH MACULO-PAPULAR 19 0.0009
566 ESCHERICHIA INFECTION 7 0.0009
567 PANCREATITIS ACUTE 19 0.0008
568 SINUS TACHYCARDIA 12 0.0008
569 MUSCLE INJURY 7 0.0008
570 CHRONIC LYMPHOCYTIC LEUKAEMIA 4 0.0008
571 LUNG INFECTION 13 0.0008
572 HYPOVOLAEMIC SHOCK 4 0.0008
573 RESPIRATORY DISTRESS 23 0.0008
574 HEPATITIS B 5 0.0008
575 GUILLAIN-BARRE SYNDROME 4 0.0008
576 BONE PAIN 48 0.0008
577 HYPOTENSION 162 0.0008
578 ILEUS 10 0.0008
579 SKIN INFECTION 9 0.0008
580 HYPOMAGNESAEMIA 11 0.0008
581 HYPERTHERMIA 6 0.0008
582 DEATH 674 0.0008
583 INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION 8 0.0008
584 TORSADE DE POINTES 6 0.0008
585 LYMPHADENOPATHY 27 0.0008
586 PRODUCT PREPARATION ISSUE 5 0.0008
587 SARS-COV-2 TEST POSITIVE 10 0.0008
588 FULL BLOOD COUNT ABNORMAL 8 0.0008
589 POLYNEUROPATHY 9 0.0008
590 TRANSPLANT REJECTION 6 0.0007
591 POST PROCEDURAL INFECTION 6 0.0007
592 TACHYPNOEA 10 0.0007
593 HYPERKERATOSIS 4 0.0007
594 HEMIPLEGIA 6 0.0007
595 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 51 0.0007
596 RENAL IMPAIRMENT 60 0.0007
597 ACUTE PULMONARY OEDEMA 4 0.0007
598 FACE OEDEMA 12 0.0007
599 HEPATOCELLULAR INJURY 10 0.0007
600 ABSCESS LIMB 3 0.0007
601 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 142 0.0007
602 PNEUMONITIS 19 0.0007
603 PNEUMOTHORAX 11 0.0007
604 PULMONARY OEDEMA 31 0.0007
605 ORAL CANDIDIASIS 9 0.0007
606 DECREASED INTEREST 4 0.0007
607 HAEMOLYTIC ANAEMIA 6 0.0007
608 DRUG-INDUCED LIVER INJURY 21 0.0007
609 VENTRICULAR TACHYCARDIA 11 0.0007
610 COGNITIVE DISORDER 31 0.0007
611 ADRENAL INSUFFICIENCY 8 0.0007
612 TROPONIN INCREASED 5 0.0007
613 HAEMODYNAMIC INSTABILITY 5 0.0007
614 CENTRAL NERVOUS SYSTEM LESION 9 0.0007
615 UPPER RESPIRATORY TRACT INFECTION 30 0.0006
616 MALIGNANT NEOPLASM PROGRESSION 66 0.0006
617 APPENDICITIS 6 0.0006
618 INTERSTITIAL LUNG DISEASE 31 0.0006
619 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 35 0.0006
620 HOSPITALISATION 98 0.0006
621 GINGIVAL PAIN 5 0.0006
622 COVID-19 110 0.0006
623 SUPRAVENTRICULAR TACHYCARDIA 6 0.0006
624 METASTASES TO LIVER 11 0.0006
625 ENTERITIS 4 0.0006
626 PNEUMONIA 201 0.0006
627 MENTAL DISORDER 27 0.0006
628 METASTASES TO CENTRAL NERVOUS SYSTEM 8 0.0006
629 LIVER FUNCTION TEST ABNORMAL 18 0.0006
630 INCOHERENT 4 0.0006
631 NEURALGIA 15 0.0006
632 BRADYPHRENIA 4 0.0006
633 NEOPLASM 7 0.0006
634 HOSPICE CARE 6 0.0006
635 HEADACHE 379 0.0006
636 DRUG LEVEL INCREASED 10 0.0006
637 PERICARDITIS 10 0.0006
638 AGRANULOCYTOSIS 11 0.0006
639 MELAENA 13 0.0006
640 MOTOR DYSFUNCTION 6 0.0006
641 ACUTE KIDNEY INJURY 90 0.0006
642 CHOLECYSTITIS 7 0.0006
643 CIRCULATORY COLLAPSE 10 0.0006
644 MYOCLONUS 7 0.0006
645 EUPHORIC MOOD 6 0.0006
646 EYE MOVEMENT DISORDER 4 0.0006
647 BLOOD MAGNESIUM DECREASED 5 0.0006
648 APLASTIC ANAEMIA 3 0.0006
649 DEMENTIA 16 0.0006
650 MASS 8 0.0006
651 OEDEMA 31 0.0006
652 TOXICITY TO VARIOUS AGENTS 96 0.0006
653 PAPULE 4 0.0006
654 DRUG ERUPTION 10 0.0006
655 ANAL ABSCESS 3 0.0006
656 DEVICE LEAKAGE 24 0.0006
657 LUNG DISORDER 27 0.0006
658 PATHOGEN RESISTANCE 5 0.0005
659 HEPATITIS 14 0.0005
660 MOUTH HAEMORRHAGE 4 0.0005
661 INFUSION RELATED REACTION 36 0.0005
662 DRUG INTOLERANCE 52 0.0005
663 RESPIRATORY TRACT INFECTION 14 0.0005
664 ANGIOPATHY 3 0.0005
665 HALLUCINATION 40 0.0005
666 PULMONARY HYPERTENSION 11 0.0005
667 ILL-DEFINED DISORDER 32 0.0005
668 DISSOCIATION 4 0.0005
669 PNEUMONIA ASPIRATION 13 0.0005
670 LYMPHOMA 8 0.0005
671 ELECTROLYTE IMBALANCE 6 0.0005
672 BLOOD PRESSURE DECREASED 34 0.0005
673 INFLAMMATORY BOWEL DISEASE 5 0.0005
674 BLOOD TRIGLYCERIDES INCREASED 9 0.0005
675 RHEUMATOID ARTHRITIS 57 0.0005
676 COORDINATION ABNORMAL 7 0.0005
677 MUSCULAR WEAKNESS 57 0.0005
678 BLOOD DISORDER 4 0.0005
679 OXYGEN SATURATION DECREASED 28 0.0005
680 OSTEOMYELITIS 9 0.0005
681 SKIN REACTION 7 0.0005
682 DRUG EFFECT INCOMPLETE 18 0.0005
683 LETHARGY 28 0.0005
684 VENTRICULAR EXTRASYSTOLES 5 0.0005
685 FLUID OVERLOAD 7 0.0005
686 CARDIAC FAILURE 38 0.0005
687 URINARY INCONTINENCE 14 0.0005
688 SOMNOLENCE 95 0.0005
689 PULMONARY MASS 7 0.0005
690 HAEMATURIA 16 0.0005
691 SKIN HYPERPIGMENTATION 4 0.0005
692 EPISTAXIS 34 0.0005
693 VIRAL INFECTION 15 0.0005
694 CEREBRAL INFARCTION 11 0.0004
695 VENTRICULAR FIBRILLATION 5 0.0004
696 URINARY RETENTION 15 0.0004
697 HAEMOGLOBIN DECREASED 46 0.0004
698 DEEP VEIN THROMBOSIS 29 0.0004
699 TRANSIENT ISCHAEMIC ATTACK 15 0.0004
700 COMA 21 0.0004
701 MYOCARDITIS 5 0.0004
702 PNEUMONIA BACTERIAL 4 0.0004
703 MUSCULOSKELETAL DISORDER 8 0.0004
704 RED BLOOD CELL COUNT DECREASED 12 0.0004
705 PARALYSIS 6 0.0004
706 BLOOD UREA INCREASED 7 0.0004
707 PULMONARY FIBROSIS 8 0.0004
708 POST PROCEDURAL COMPLICATION 8 0.0004
709 HYPERTENSION 88 0.0004
710 INCORRECT PRODUCT ADMINISTRATION DURATION 9 0.0004
711 ATELECTASIS 4 0.0004
712 SINUS BRADYCARDIA 4 0.0004
713 INJECTION SITE HAEMORRHAGE 33 0.0004
714 SCHIZOPHRENIA 5 0.0004
715 AUTOIMMUNE DISORDER 4 0.0004
716 VITAMIN D DEFICIENCY 4 0.0004
717 ORAL HERPES 8 0.0004
718 THERAPY CHANGE 4 0.0004
719 RENAL INJURY 12 0.0004
720 GENERALISED OEDEMA 5 0.0004
721 HAEMATOCRIT DECREASED 8 0.0004
722 LACTIC ACIDOSIS 13 0.0004
723 OSTEOPENIA 6 0.0004
724 AGITATION 29 0.0004
725 EYELID PTOSIS 4 0.0004
726 ACIDOSIS 3 0.0004
727 HAEMORRHAGE 41 0.0004
728 HYPOPHAGIA 10 0.0004
729 TEMPERATURE INTOLERANCE 4 0.0004
730 SKIN ULCER 10 0.0004
731 APHTHOUS ULCER 3 0.0004
732 EJECTION FRACTION DECREASED 6 0.0004
733 BASAL CELL CARCINOMA 6 0.0004
734 PETECHIAE 4 0.0004
735 ARTERIAL OCCLUSIVE DISEASE 3 0.0004
736 HYPOAESTHESIA 57 0.0004
737 ADVERSE DRUG REACTION 34 0.0004
738 JAUNDICE 10 0.0004
739 THERAPY INTERRUPTED 26 0.0004
740 PSYCHOMOTOR HYPERACTIVITY 6 0.0004
741 BLOOD CALCIUM DECREASED 4 0.0004
742 HYPONATRAEMIA 20 0.0004
743 HAEMATEMESIS 9 0.0004
744 GASTROENTERITIS 5 0.0003
745 MOVEMENT DISORDER 11 0.0003
746 MEMORY IMPAIRMENT 47 0.0003
747 DRUG INEFFECTIVE 448 0.0003
748 SYNCOPE 34 0.0003
749 RASH 148 0.0003
750 CARDIOMYOPATHY 5 0.0003
751 CELLULITIS 17 0.0003
752 GENERAL PHYSICAL HEALTH DETERIORATION 39 0.0003
753 ISCHAEMIC STROKE 6 0.0003
754 CHOLELITHIASIS 11 0.0003
755 HYPERLIPIDAEMIA 4 0.0003
756 BLOOD POTASSIUM DECREASED 10 0.0003
757 MENTAL IMPAIRMENT 8 0.0003
758 RESTLESSNESS 12 0.0003
759 VOMITING 153 0.0003
760 MUSCULOSKELETAL CHEST PAIN 5 0.0003
761 BRADYCARDIA 17 0.0003
762 ATRIAL FIBRILLATION 31 0.0003
763 MYALGIA 54 0.0003
764 ASTHENIA 119 0.0003
765 PULMONARY EMBOLISM 30 0.0003
766 HERPES ZOSTER 18 0.0003
767 HEART RATE INCREASED 31 0.0003
768 AFFECT LABILITY 3 0.0003
769 CARDIO-RESPIRATORY ARREST 13 0.0003
770 INFUSION SITE PAIN 4 0.0003
771 INFLAMMATION 16 0.0003
772 DYSTONIA 6 0.0003
773 BLOOD CREATININE INCREASED 20 0.0003
774 DEAFNESS 8 0.0003
775 INCORRECT PRODUCT STORAGE 4 0.0003
776 IMMUNE SYSTEM DISORDER 4 0.0003
777 RENAL FAILURE 40 0.0003
778 BALANCE DISORDER 26 0.0003
779 THROMBOSIS 24 0.0003
780 THERAPEUTIC RESPONSE DECREASED 18 0.0003
781 FEEDING DISORDER 6 0.0003
782 RASH ERYTHEMATOUS 14 0.0003
783 THERAPEUTIC PRODUCT EFFECT DECREASED 13 0.0003
784 GASTROINTESTINAL DISORDER 26 0.0003
785 FEELING COLD 8 0.0003
786 APHONIA 4 0.0003
787 HALLUCINATION, VISUAL 6 0.0003
788 DIALYSIS 4 0.0003
789 BRONCHOSPASM 4 0.0003
790 PARAESTHESIA 44 0.0003
791 ELECTROCARDIOGRAM QT PROLONGED 10 0.0003
792 ABNORMAL BEHAVIOUR 11 0.0003
793 ABDOMINAL PAIN LOWER 7 0.0003
794 AMNESIA 18 0.0003
795 CARDIOVASCULAR DISORDER 7 0.0003
796 ABDOMINAL PAIN 64 0.0003
797 INTERVERTEBRAL DISC PROTRUSION 6 0.0003
798 OSTEONECROSIS 9 0.0003
799 ACCIDENTAL OVERDOSE 10 0.0003
800 HAEMATOMA 7 0.0003
801 SKIN DISORDER 9 0.0003
802 HEPATIC STEATOSIS 5 0.0003
803 THINKING ABNORMAL 5 0.0003
804 RASH PAPULAR 6 0.0003
805 GAIT DISTURBANCE 51 0.0003
806 GASTRITIS 7 0.0003
807 HYPOAESTHESIA ORAL 4 0.0003
808 DEVICE USE ERROR 9 0.0003
809 LOSS OF CONSCIOUSNESS 33 0.0003
810 HALLUCINATION, AUDITORY 4 0.0003
811 ABSCESS 4 0.0003
812 MUSCULOSKELETAL PAIN 13 0.0002
813 BLOOD POTASSIUM INCREASED 4 0.0002
814 PAIN IN EXTREMITY 72 0.0002
815 HYPERSOMNIA 7 0.0002
816 CARDIAC ARREST 20 0.0002
817 DYSSTASIA 7 0.0002
818 GASTROINTESTINAL HAEMORRHAGE 20 0.0002
819 UPPER GASTROINTESTINAL HAEMORRHAGE 4 0.0002
820 PSYCHOTIC DISORDER 7 0.0002
821 BACK PAIN 55 0.0002
822 EATING DISORDER 5 0.0002
823 EXPOSURE VIA SKIN CONTACT 6 0.0002
824 BLISTER 13 0.0002
825 DIPLOPIA 6 0.0002
826 HYPERKALAEMIA 8 0.0002
827 CONSTIPATION 49 0.0002
828 DYSPHAGIA 21 0.0002
829 HYPOTHYROIDISM 7 0.0002
830 TINNITUS 10 0.0002
831 DIVERTICULITIS 6 0.0002
832 FLUID RETENTION 11 0.0002
833 BLOOD SODIUM DECREASED 4 0.0002
834 MALAISE 93 0.0002
835 FRACTURE 4 0.0002
836 ARRHYTHMIA 10 0.0002
837 DECREASED APPETITE 49 0.0002
838 INTERNATIONAL NORMALISED RATIO INCREASED 6 0.0002
839 DEVICE DISLOCATION 9 0.0002
840 FLUSHING 21 0.0002
841 APATHY 3 0.0002
842 SINUSITIS 21 0.0002
843 DRUG EFFECT DECREASED 11 0.0002
844 ACUTE MYOCARDIAL INFARCTION 6 0.0002
845 NAUSEA 161 0.0002
846 ACTIVITIES OF DAILY LIVING IMPAIRED 4 0.0002
847 BLOOD GLUCOSE INCREASED 38 0.0002
848 BLOOD PRESSURE ABNORMAL 4 0.0002
849 DEVICE ISSUE 18 0.0002
850 RESPIRATORY DISORDER 6 0.0002
851 AGGRESSION 10 0.0002
852 IRRITABILITY 12 0.0002
853 DYSKINESIA 8 0.0002
854 EYE PAIN 11 0.0002
855 ANAPHYLACTIC SHOCK 5 0.0002
856 URINARY TRACT INFECTION 33 0.0002
857 FATIGUE 150 0.0002
858 CRYING 7 0.0002
859 ARTHRALGIA 79 0.0002
860 MOUTH ULCERATION 4 0.0002
861 CEREBROVASCULAR ACCIDENT 32 0.0002
862 DEHYDRATION 25 0.0002
863 DRY SKIN 25 0.0002
864 NIGHT SWEATS 6 0.0002
865 INCORRECT DOSE ADMINISTERED 42 0.0002
866 PRODUCT DISPENSING ERROR 4 0.0002
867 EYE DISORDER 6 0.0002
868 RESPIRATORY ARREST 5 0.0002
869 MOBILITY DECREASED 13 0.0002
870 GAIT INABILITY 6 0.0002
871 PLASMA CELL MYELOMA 7 0.0002
872 UNDERDOSE 13 0.0002
873 PAIN IN JAW 5 0.0002
874 PRODUCT AVAILABILITY ISSUE 4 0.0002
875 OEDEMA PERIPHERAL 21 0.0002
876 ECZEMA 9 0.0002
877 BLINDNESS 7 0.0002
878 NEEDLE ISSUE 5 0.0002
879 DIARRHOEA 110 0.0002
880 DYSPNOEA 94 0.0002
881 SKIN EXFOLIATION 14 0.0002
882 LOCALISED INFECTION 4 0.0002
883 BLOOD PRESSURE INCREASED 25 0.0002
884 PRODUCT DOSE OMISSION ISSUE 48 0.0002
885 DYSURIA 6 0.0002
886 DRUG ADMINISTRATION ERROR 5 0.0002
887 ABASIA 4 0.0002
888 PRODUCT USE IN UNAPPROVED INDICATION 40 0.0002
889 DRY MOUTH 13 0.0002
890 CHEST PAIN 29 0.0002
891 HYPERHIDROSIS 20 0.0002
892 VISUAL ACUITY REDUCED 5 0.0002
893 RENAL DISORDER 7 0.0002
894 CONDITION AGGRAVATED 45 0.0001
895 ANGER 5 0.0001
896 PRODUCTIVE COUGH 7 0.0001
897 COUGH 41 0.0001
898 VISUAL IMPAIRMENT 18 0.0001
899 HYPOGLYCAEMIA 7 0.0001
900 DIABETES MELLITUS 11 0.0001
901 PROCEDURAL PAIN 4 0.0001
902 MEDICATION ERROR 8 0.0001
903 HAEMOPTYSIS 4 0.0001
904 PERIPHERAL SWELLING 22 0.0001
905 HEART RATE DECREASED 5 0.0001
906 PRODUCT DOSE OMISSION IN ERROR 4 0.0001
907 HYPOACUSIS 6 0.0001
908 DRUG INTERACTION 22 0.0001
909 PRODUCT USE ISSUE 26 0.0001
910 SWELLING FACE 9 0.0001
911 THERAPY CESSATION 7 0.0001
912 DIZZINESS 68 0.0001
913 WEIGHT DECREASED 38 0.0001
914 INFLUENZA 15 0.0001
915 HOT FLUSH 10 0.0001
916 INTESTINAL OBSTRUCTION 5 0.0001
917 DISCOMFORT 8 0.0001
918 VISION BLURRED 18 0.0001
919 LIMB DISCOMFORT 4 0.0001
920 FEMUR FRACTURE 4 0.0001
921 RASH PRURITIC 7 0.0001
922 PAIN 79 0.0001
923 CARDIAC DISORDER 12 0.0001
924 HAEMATOCHEZIA 7 0.0001
925 ANXIETY 36 0.0001
926 CYSTITIS 4 0.0001
927 METABOLIC ACIDOSIS 4 0.0001
928 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 6 0.0001
929 HIP FRACTURE 4 0.0001
930 EXTRA DOSE ADMINISTERED 5 0.0001
931 MUSCLE SPASMS 22 0.0001
932 CATARACT 7 0.0001
933 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 21 0.0001
934 OVERDOSE 25 0.0001
935 NERVOUSNESS 6 0.0001
936 FALL 38 0.0001
937 DEVICE MALFUNCTION 8 0.0001
938 FEELING ABNORMAL 27 0.0001
939 DISTURBANCE IN ATTENTION 6 0.0001
940 TREATMENT NONCOMPLIANCE 6 0.0001
941 INFLUENZA LIKE ILLNESS 9 0.0001
942 SKIN DISCOLOURATION 5 0.0001
943 EYE SWELLING 4 0.0001
944 NECK PAIN 6 0.0001
945 ABDOMINAL PAIN UPPER 22 0.0001
946 ILLNESS 11 0.0001
947 DYSPNOEA EXERTIONAL 4 0.0001
948 OCULAR HYPERAEMIA 5 0.0001
949 NEOPLASM MALIGNANT 7 0.0001
950 VERTIGO 6 0.0001
951 CHEST DISCOMFORT 10 0.0001
952 INSOMNIA 26 0.0001
953 ERYTHEMA 20 0.0001
954 ABDOMINAL DISTENSION 10 0.0001
955 DEPRESSED MOOD 5 0.0001
956 CHRONIC KIDNEY DISEASE 7 0.0001
957 INTENTIONAL PRODUCT MISUSE 8 0.0001
958 COLITIS ULCERATIVE 4 0.0001
959 ALOPECIA 17 0.0001
960 HYPERSENSITIVITY 16 0.0001
961 WHEEZING 5 0.0001
962 MIGRAINE 8 0.0001
963 WEIGHT INCREASED 18 0.0001
964 RHINORRHOEA 5 0.0001
965 PALPITATIONS 9 0.0001
966 MYOCARDIAL INFARCTION 13 0.0001
967 EMOTIONAL DISTRESS 9 0.0001
968 CONTUSION 7 0.0001
969 NASOPHARYNGITIS 13 0.0001
970 PRURITUS 27 0.0001
971 MUSCULOSKELETAL STIFFNESS 6 0.0001
972 NASAL CONGESTION 4 0.0001
973 ANGIOEDEMA 3 0.0001
974 SWELLING 6 0.0001
975 CARDIAC FAILURE CONGESTIVE 5 0.0001
976 GASTROOESOPHAGEAL REFLUX DISEASE 5 0.0001
977 INTENTIONAL PRODUCT USE ISSUE 5 0.0001
978 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 4 0.0001
979 SUICIDAL IDEATION 5 0.0001
980 ANAPHYLACTIC REACTION 3 0.0001
981 ASTHMA 6 0.0001
982 DEPRESSION 12 0.0001
983 DYSPEPSIA 5 0.0001
984 JOINT SWELLING 6 0.0000
985 OROPHARYNGEAL PAIN 4 0.0000
986 ABDOMINAL DISCOMFORT 7 0.0000
987 ARTHRITIS 3 0.0000
988 NO ADVERSE EVENT 6 0.0000
989 PSORIASIS 4 0.0000
990 URTICARIA 5 0.0000
991 DRUG DOSE OMISSION 4 0.0000